Skip to main content
All Posts By

admin

emergent logo

Emergent BioSolutions Receives Department of Defense Award

By News Archive

emergent logoGAITHERSBURG, Md., Nov. 14, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today a research award by the U.S. Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) to evaluate efficacy of the company’s single-dose chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate. Emergent will begin the planning phase, the first of two phases, in collaboration with the Armed Forces Research Institute of Medical Sciences (AFRIMS) and academic partners, to enable a post-approval field efficacy study in areas with active chikungunya virus (CHIKV) transmission.

Read More
Bruce Jarrell, MD, FACS

University of Maryland Strategic Partnership Announces New Institute to Transform Medicine Using Big Data and Artificial Intelligence Technologies | University of Maryland School of Medicine

By News Archive

Bruce Jarrell, MD, FACSThe University of Maryland Strategic Partnership: MPowering the State (MPower) today announced a transformative partnership to establish the University of Maryland 3 – Institute for Health Computing (UM-3-IHC), which is being led by the University of Maryland, Baltimore (UMB) and the University of Maryland, College Park (UMCP), in collaboration with the University of Maryland Medical System (UMMS) and Montgomery County, Md. This new Institute will leverage recent advances in artificial intelligence (AI) and computing to create a premier learning health care system that evaluates both de-identified and secure digitized medical health data to diagnose, prevent and treat diseases in patients across the state of Maryland.

Image: Bruce Jarrell, MD, FACS

Read More
Montgomery County to establish Institute for Health Computing in North Bethesda Washington Business Journal

Montgomery County to establish Institute for Health Computing in North Bethesda – Washington Business Journal

By News Archive

Montgomery County to establish Institute for Health Computing in North Bethesda Washington Business Journal

Montgomery County Executive Marc Elrich signed Thursday a multiagency agreement to launch a new higher education institute in North Bethesda dedicated to artificial intelligence in health care, with the goal of establishing a magnetic academic-industrial complex akin to what’s envisioned for Northern Virginia’s National Landing.

The budding collaboration — dubbed The University of Maryland 3 – Institute for Health Computing, or UM-3-IHC — involves Montgomery County, the University of Maryland campuses in Baltimore and College Park and the University of Maryland Medical System Corporation (UMMS), a hospital network. 

Image: https://www.bizjournals.com/

Read More
Johnson Johnson Logo

Johnson & Johnson Innovation Names Awardees in the Innovations for Vets QuickFire Challenge: Lung Cancer & Physical Trauma | Johnson & Johnson Innovation

By News Archive

Johnson Johnson LogoNovember 9, 2022 — Johnson & Johnson Innovation, together with Johnson & Johnson Office of Military and Veterans Affairs, announced that AmacaThera, Hawkeye Bio, Inc., Garwood Medical Devices, LLC, Immunophotonics, Limax Biosciences, and Nanochon have been selected as the awardees in the Innovations for Vets QuickFire Challenge: Lung Cancer & Physical Trauma.

The challenge invited innovators to submit potentially groundbreaking ideas that aim to directly address the unique healthcare needs of the military community.

 

Read More
The ESM Metagenomic Atlas contains structural predictions for 617 million proteins.Credit: ESM Metagenomic Atlas (CC BY 4.0)

AlphaFold’s new rival? Meta AI predicts shape of 600 million proteins

By News Archive

The ESM Metagenomic Atlas contains structural predictions for 617 million proteins.Credit: ESM Metagenomic Atlas (CC BY 4.0)When London-based artificial-intelligence (AI) company DeepMind unveiled predicted structures for some 220 million proteins earlier this year, the trove covered nearly every protein from known organisms in DNA databases. Now, another tech giant is filling in the ‘dark matter’ of the protein universe.

Researchers at Meta (formerly Facebook, headquartered in Menlo Park, California) have used AI to predict the structures of some 600 million proteins from bacteria, viruses and other microorganisms that haven’t been characterized.

Image: The ESM Metagenomic Atlas contains structural predictions for 617 million proteins.Credit: ESM Metagenomic Atlas (CC BY 4.0)

Read More
Aimee Smart

Aimee Smart

By Uncategorized

Vice President of Clinical Development and Regulatory Processes at Lung Biotechnology PBC and Lung Bioengineering Inc (subsidiaries of United Therapeutics Corporation)

Aimee Smart

Aimee Smart is an accomplished senior executive with more than 20 years of success in the pharmaceutical and biotechnology industries, Aimee enjoys leading deeply challenging projects where there is no clear path forward. She understands how to work with many people across various functions, operate under high pressure, and meet critical timelines to deliver results. And because everything she does in regulatory strategy, designing, and running clinical development programs is years in the making, her complex problem-solving ability includes considering the world of today while anticipating what might happen in the future.

In her current role of Vice President of Clinical Development and Regulatory Processes at LungBiotechnology PBC and Lung Bioengineering Inc (subsidiaries of United TherapeuticsCorporation), Aimee reports directly to the parent company CEO, driving clinical drug development and leading a multifunctional organization and a geographically dispersed team of ver 60 professionals, covering all aspects of development including; regulatory affairs, quality assurance, clinical development, product development, clinical supply, clinical operations, biostatistics and data management, and project management.

Aimee is part of the executive leadership team of United Therapeutics Corporation, representing her companies needs at the corporate level. She was responsible for Lung Biotechnology’sreorganization and setting its new strategic goals. And after leading the successful turnaround of the underperforming subsidiary to a respected, productive company, Aimee’s CEO asked he rto do it a second time and lead the Lung Bioengineering subsidiary.

During her more than 14-year tenure at Lung Biotechnology PBC, Aimee has served in increasingly senior clinical development, regulatory affairs and quality roles, including as Associate Vice President and Head of Office and Director, Global Regulatory Affairs. Her experience also includes regulatory affairs posts at VIRxSYS Corporation, Human GenomeSciences, Nabi Biopharmaceuticals, and Cato Research.

As much as she enjoys solving complex problems and driving results, Aimee is most passionate about ensuring that what she is doing is connected back to a meaningful mission that directly impacts people’s lives in a positive way.

Aimee earned her Bachelor of Science in Microbiology from North Carolina State University, where she was later honored with its Outstanding Young Alumni award. She completed her executive MBA from the University of Maryland in 2022 and was named one of the Best and brightest EMBA students by Poets & Quants magazine. In addition, Aimee holds certifications in Leadership Coaching for Organizational Performance from American University and in Regulatory Affairs for the U.S. and Europe from the Regulatory Affairs Professional Society.

She maintains professional memberships in the Drug Information Association, RegulatoryAffairs Professional Society, Women in Bio, and International Coach Federation. She also serves as a Member for the NCSU College of Sciences Foundations Board.

Immunimic Therapeutics Logo

Immunomic Therapeutics, Inc. Receives FDA Fast Track Designation for ITI-3000, a pDNA Vaccine, in Development for the Treatment of Merkel Cell Carcinoma

By News Archive

Immunimic Therapeutics LogoNovember 08, 2022 08:30 AM Eastern Standard Time

ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the ITI-3000 program for the treatment of patients with Merkel cell carcinoma. The company is currently enrolling a phase 1 study evaluating ITI-3000, a plasmid DNA (pDNA) vaccine targeting patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer that is typically caused by the Merkel cell polyomavirus (MCPyV).

“The FDA’s decision to grant FTD underscores the potential for the ITI-3000 program to address a serious unmet need and serve as a meaningful therapeutic option for patients with Merkel cell carcinoma,” stated Dr. William Hearl, Chief Executive Officer of ITI. “We are committed to unlocking the full potential of ITI-3000 in patients with this aggressive form of skin cancer. We expect to report top-line data from our ongoing phase 1 trial of ITI-3000 in MCC patients next year and look forward to working closely with the FDA on a potential next phase clinical study design, while simultaneously continuing dialogue with possible partners.”

Read More
VogelsteinPetrocheilos 1

Catalio Capital Management’s new $85M fund is financing biomedical founders in ‘special situations’ – Technical.ly

By News Archive

VogelsteinPetrocheilos 1Catalio Capital Management, an investment firm with offices in Baltimore and New York City, this week announced the close of a new fund that already counts a Johns Hopkins University-borne cancer detection company and patient-monitoring software system in its portfolio.

According to Catalio executives, the $85 million Catalio Credit Opportunities Fund I partners with what a statement called “39 world-renowned serial scientist-entrepreneurs at top-tier academic institutions in the US and Europe in order to vet opportunities to fund founders.” The fund, also described as a “special situations fund,” targets small and mid-sized private companies.

Image: (L to R) Catalio Capital Management cofounders R. Jacob Vogelstein and George Petrocheilos.

(Courtesy photo)

Read More
Linshom medical logo

Linshom Medical awarded $2.4M SBIR Fasttrack award from NIH (NHLBI) – World News Report – EIN Presswire

By News Archive

Linshom medical logoBALTIMORE, MARYLAND, UNITED STATES, November 8, 2022 /EINPresswire.com/ — Linshom Medical was awarded a $2.4 Million Fasttrack SBIR grant from the National Institutes of Health (NIH), National Heart Lung and Blood Institute (NHLBI).

“This award further validates our technology for critical bedside respiratory monitoring and adds to the list of Linshom Medical’s achievements,” said Richard Hughen, CEO. “This award funds a clinical study to prove Linshom’s early detection capability of patient respiratory decline. It also funds the further miniaturization of our technology to reach more patients in more settings such as a nasal cannula and a wearable sensor for home monitoring.”

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.